- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01212380
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL)
RATIONALE:
Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE:
This phase I trial is studying the side effects and the best dose of carfilzomib in treating patients with relapsed or refractory chronic lymphocytic leukemia(CLL),small lymphocytic lymphoma(SLL), or prolymphocytic leukemia (PLL).
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the dose limiting toxicity (DLT) and maximal tolerated dose (MTD) of carfilzomib in patients with relapsed or refractory Chronic Lymphocytic Leukemia(CLL) / Small Lymphocytic Lymphoma (SLL) and Prolymphocytic Leukemia (PLL).
II. To evaluate the safety and toxicity profile of carfilzomib in relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)/prolymphocytic leukemia (PLL).
SECONDARY OBJECTIVES:
I. To evaluate efficacy of carfilzomib therapy in relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)/prolymphocytic leukemia (PLL) to justify future phase II studies.
II. To determine the degree and duration of cellular proteosome inhibition induced by carfilzomib and relationship of this to pharmacodynamics, response and toxicity.
III. To determine the pharmacokinetics (plasma and cellular) of carfilzomib and relationship of this to proteosome inhibition, pharmacodynamics, response, and toxicity.IV. To examine the effect of carfilzomib on pharmacodynamic parameters including cytokines, changes in downstream targets including NF-kappa B (p50/p65 binding; I-kappa B level, P-I-kappa B level,select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), ER stress proteins, and p73.
OUTLINE: This is a dose-escalation study of carfilzomib.Patients receiving carfilzomib intra-venous(IV) over 30 minutes once daily, on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Previously treated patients with a diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic leukemia (PLL) by NCI Criteria with intermediate or high risk B-Cell chronic lymphocytic leukemia (CLL)(Modified Rai stage) satisfying at least one of the criteria for active disease requiring treatment;patients with a history of Richter's transformation are eligible if they now have evidence of chronic lymphocytic leukemia (CLL) only, with < 10% large cells in the bone marrow
- Massive or progressive splenomegaly and/or lymphadenopathy; or need for cytoreduction for stem cell transplant
- Anemia (hemoglobin < 11 g/dl) or thrombocytopenia (platelets < 100 x 10^9/L)
- Presence of weight loss > 10% over the preceding 6 month period
- NCI grade 2 or 3 fatigue
- Fevers > 100.5 °C or night sweats for greater than 2 weeks without evidence of infection
- Progressive lymphocytosis with an increase of > 50% over a 2 month period or an anticipated doubling time of less than 6 months
- Creatinine Clearance (CrCl) > 15mL/min
- Alanine aminotransferase (ALT) < 3X upper limit of normal (ULN)
- Bilirubin =< 2 times the upper limit of normal, unless disease related
- Platelets >= 20 x 10^9/L and absence of active bleeding
- Patients must have an ECOG (Eastern Cooperative Oncology Group) performance status =< 2
- Patients must not have secondary cancers that result in a life expectancy of <2 years or that would confound assessment of toxicity in this study
- Patients of all racial/ethnic groups are eligible for the study if they meet eligibility criteria outlined-
- Patients must provide written informed consent
Exclusion Criteria:
- Absence of previously treated chronic lymphocytic leukemia (CLL)
- Female subject that is pregnant or breastfeeding; women of childbearing potential and men must agree to use adequate contraception prior to study entry, duration of study participation,and 30 days following study completion; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately;confirmation that the subject is not pregnant must be established by a negative serum -human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women
- Patients with congestive heart failure (CHF)in whom pre-treatment hydration would be prohibitive;New York Heart Association (NYHA) Class III/IV CHF is excluded
- Patients who have had treatment for chronic lymphocytic leukemia (CLL) within 2 weeks, although palliative steroids are acceptable
- Patient unable to give written informed consent
- Failure to recover from toxicity of previous radiotherapy or chemotherapy to grade 1
- Patients with active infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study until resolution of the infection; patients on prophylactic antibiotics or antivirals are acceptable
- Patients who have previously taken bortezomib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1
Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16.
Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
|
Given IV infusion lasting 30 minutes.
Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16).
The first and second dose will always be administered at 20 mg/m2.
Other Names:
TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment.
These will be assessed utilizing standard ELISA or flow cytometry methodology.
Other cytokines or soluble factors may be assessed that relate to drug toxicity or response.
After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined.
Cytokines will be examined by a multiplex flow cytometry assay or ELISA.
Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
Other Names:
Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release.
These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients).
These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response.
Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
Other Names:
Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
Other Names:
Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy.
Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies.
SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined.
Other SNPs may be used in the future.
Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine safety of carfilzomib by evaluating the toxicity profile.
Time Frame: Up to 24 months
|
The safe use of carfilzomib will be assessed by:
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of Carfilzomib therapy in relapsed or refractory chromic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)/prolymphocytic leukemia (PLL)
Time Frame: Up to 24 months
|
Efficacy of this therapy is evaluated by:
|
Up to 24 months
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-09108
- NCI-2010-01884 (REGISTRY: CTRP (Clinical Trial Registration Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic/Lymphoid Cancer
-
Leland MethenyAvailableHematopoietic/Lymphoid CancerUnited States
-
ImCheck TherapeuticsRecruitingHematopoietic/Lymphoid Cancer | Solid Tumor, AdultFrance, Belgium, United States, Germany, Spain, United Kingdom
-
M.D. Anderson Cancer CenterAmgenTerminatedHematopoietic/Lymphoid Cancer | Richter's TransformationUnited States
-
University of Colorado, DenverPatient-Centered Outcomes Research InstituteCompletedHematopoietic/Lymphoid CancerUnited States
-
Cancer Research UKUnknownHematopoietic/Lymphoid CancerUnited Kingdom
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedHematopoietic/Lymphoid CancerUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedPain | Hematopoietic/Lymphoid CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cancer | SurvivorshipUnited States
-
University of California, San FranciscoSwim Across AmericaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Childhood CancerUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownHematopoietic/Lymphoid CancerFrance
Clinical Trials on carfilzomib
-
Ajai ChariAmgenCompletedRefractory Multiple Myeloma | Relapse Multiple MyelomaUnited States
-
M.D. Anderson Cancer CenterOnyx Therapeutics, Inc.TerminatedLymphomaUnited States
-
University of ArkansasOnyx Therapeutics, Inc.No longer available
-
AmgenCompleted
-
Thomas LundRecruiting
-
Washington University School of MedicineCompleted
-
NovartisAmgenTerminated
-
M.D. Anderson Cancer CenterOnyx Therapeutics, Inc.Completed
-
AmgenCompletedMultiple MyelomaUnited States, Canada
-
AmgenCompletedHepatic Impairment | Solid Tumors | Hematologic MalignanciesUnited Kingdom, Netherlands, United States, France